Total Payments
$333,013
2024 Payments
$155,036
Companies
13
Transactions
158
Medicare Patients
355
Medicare Billing
$43,775
Payment Breakdown by Category
Consulting$123,187 (37.0%)
Research$121,945 (36.6%)
Other$75,665 (22.7%)
Travel$7,968 (2.4%)
Food & Beverage$4,248 (1.3%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $123,187 | 22 | 37.0% |
| Unspecified | $121,945 | 1 | 36.6% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $64,150 | 32 | 19.3% |
| Honoraria | $9,955 | 4 | 3.0% |
| Travel and Lodging | $7,968 | 48 | 2.4% |
| Food and Beverage | $4,248 | 50 | 1.3% |
| Compensation for serving as faculty or as a speaker for a medical education program | $1,560 | 1 | 0.5% |
Payments by Type
General
$211,068
157 transactions
Research
$121,945
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Abbott Laboratories | $122,545 | 2 | $0 (2024) |
| Gilead Sciences, Inc. | $97,054 | 7 | $0 (2024) |
| AstraZeneca Pharmaceuticals LP | $56,154 | 79 | $0 (2024) |
| BioXcel Therapeutics, Inc. | $15,339 | 28 | $0 (2023) |
| Octapharma USA, Inc. | $12,569 | 15 | $0 (2024) |
| Siemens Medical Solutions USA, Inc. | $11,850 | 4 | $0 (2024) |
| Beckman Coulter, Inc. | $11,809 | 13 | $0 (2024) |
| Quidel Corporation | $3,483 | 3 | $0 (2022) |
| Advanced Circulatory Systems Inc. | $908.39 | 2 | $0 (2018) |
| Kowa Pharmaceuticals America, Inc. | $893.75 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $155,036 | 39 | Abbott Laboratories ($121,945) |
| 2023 | $58,326 | 53 | Gilead Sciences, Inc. ($18,907) |
| 2022 | $37,707 | 23 | Gilead Sciences, Inc. ($19,243) |
| 2021 | $30,852 | 23 | Gilead Sciences, Inc. ($16,691) |
| 2020 | $19,804 | 13 | Gilead Sciences, Inc. ($10,528) |
| 2019 | $5,280 | 2 | Gilead Sciences, Inc. ($5,208) |
| 2018 | $26,007 | 5 | Gilead Sciences, Inc. ($25,000) |
All Payment Transactions
158 individual payment records from CMS Open Payments — Page 1 of 7
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/31/2024 | Gilead Sciences, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,477.39 | General |
| 12/18/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Food and Beverage | In-kind items and services | $137.87 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 12/17/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Honoraria | Cash or cash equivalent | $6,040.00 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 12/17/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $786.46 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 12/17/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $240.37 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 12/17/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $36.24 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 12/17/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Food and Beverage | Cash or cash equivalent | $32.00 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 12/17/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $24.84 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 11/12/2024 | Beckman Coulter, Inc. | — | Consulting Fee | Cash or cash equivalent | $4,704.00 | General |
| 10/24/2024 | Abbott Laboratories | I-STAT (Device) | — | Cash or cash equivalent | $121,945.00 | Research |
| Study: Clinical Evaluation of the iSTAT hs-Tnl Test to Aid in the Diagnosis of Myocardial Infarction (MI) • Category: POINT OF CARE | ||||||
| 10/01/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Honoraria | Cash or cash equivalent | $3,265.00 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 10/01/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $876.95 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 10/01/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $300.46 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 10/01/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $300.46 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 10/01/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Food and Beverage | Cash or cash equivalent | $40.44 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 10/01/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Travel and Lodging | Cash or cash equivalent | $23.74 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 09/30/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Food and Beverage | In-kind items and services | $139.16 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 09/12/2024 | Octapharma USA, Inc. | BALFAXAR (Biological) | Honoraria | Cash or cash equivalent | $325.00 | General |
| Category: INTENSIVE CAREEMERGENCY | ||||||
| 05/30/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,950.00 | General |
| Category: Rare Disease | ||||||
| 05/30/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,950.00 | General |
| Category: Rare Disease | ||||||
| 05/23/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $300.00 | General |
| Category: Rare Disease | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $124.74 | General |
| Category: Rare Disease | ||||||
| 05/22/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Travel and Lodging | In-kind items and services | $26.80 | General |
| Category: Rare Disease | ||||||
| 05/20/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Food and Beverage | In-kind items and services | $121.84 | General |
| Category: Rare Disease | ||||||
| 05/20/2024 | AstraZeneca Pharmaceuticals LP | ANDEXXA (Biological) | Travel and Lodging | In-kind items and services | $67.00 | General |
| Category: Rare Disease | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Clinical Evaluation of the iSTAT hs-Tnl Test to Aid in the Diagnosis of Myocardial Infarction (MI) | Abbott Laboratories | $121,945 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 86 | 86 | $39,575 | $9,303 |
| 2022 | 3 | 71 | 72 | $41,216 | $9,931 |
| 2021 | 4 | 99 | 101 | $49,620 | $12,373 |
| 2020 | 4 | 99 | 99 | $46,707 | $12,168 |
Total Patients
355
Total Services
358
Medicare Billing
$43,775
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99285 | Emergency department visit with high level of medical decision making | Facility | 2023 | 33 | 33 | $19,470 | $4,700 | 24.1% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2023 | 16 | 16 | $12,000 | $2,693 | 22.4% |
| 99284 | Emergency department visit with moderate level of medical decision making | Facility | 2023 | 19 | 19 | $7,619 | $1,796 | 23.6% |
| 93010 | Routine electrocardiogram (ecg) using at least 12 leads with interpretation and report only | Facility | 2023 | 18 | 18 | $486.00 | $113.34 | 23.3% |
| 99285 | Emergency department visit for life threatening or functioning severity | Facility | 2022 | 45 | 45 | $26,550 | $6,561 | 24.7% |
| 99291 | Critical care, first 30-74 minutes | Facility | 2022 | 11 | 11 | $8,250 | $1,975 | 23.9% |
| 99284 | Emergency department visit for problem of high severity | Facility | 2022 | 15 | 16 | $6,416 | $1,395 | 21.7% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2021 | 41 | 41 | $24,190 | $6,574 | 27.2% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2021 | 20 | 20 | $15,000 | $3,312 | 22.1% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2021 | 25 | 25 | $10,025 | $2,393 | 23.9% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2021 | 13 | 15 | $405.00 | $94.61 | 23.4% |
| 99285 | Emergency department visit, problem with significant threat to life or function | Facility | 2020 | 45 | 45 | $26,550 | $7,022 | 26.4% |
| 99291 | Critical care delivery critically ill or injured patient, first 30-74 minutes | Facility | 2020 | 15 | 15 | $11,250 | $2,783 | 24.7% |
| 99284 | Emergency department visit, problem of high severity | Facility | 2020 | 21 | 21 | $8,421 | $2,243 | 26.6% |
| 93010 | Routine electrocardiogram (ekg) using at least 12 leads with interpretation and report | Facility | 2020 | 18 | 18 | $486.00 | $119.86 | 24.7% |
About Dr. Joseph Miller, MD
Dr. Joseph Miller, MD is a Internal Medicine healthcare provider based in Detroit, Michigan. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/22/2007. The National Provider Identifier (NPI) number assigned to this provider is 1780893982.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joseph Miller, MD has received a total of $333,013 in payments from pharmaceutical and medical device companies, with $155,036 received in 2024. These payments were reported across 158 transactions from 13 companies. The most common payment nature is "Consulting Fee" ($123,187).
As a Medicare-enrolled provider, Miller has provided services to 355 Medicare beneficiaries, totaling 358 services with total Medicare billing of $43,775. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Internal Medicine
- Other Specialties Emergency Medicine
- Location Detroit, MI
- Active Since 05/22/2007
- Last Updated 01/14/2009
- Taxonomy Code 207R00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1780893982
Products in Payments
- I-STAT (Device) $122,545
- ANDEXXA (Biological) $28,054
- LOKELMA (Drug) $28,029
- IGALMI (Drug) $15,339
- BALFAXAR (Biological) $12,569
- DXI 800 (Device) $1,560
- Seglentis (Drug) $893.75
- DXH 900 Hematology System (Device) $872.03
- POCKET EEG DEVICE (Device) $237.52
- DXH 900 (Device) $113.25
- CD cobas Reagents (Device) $98.67
- Modified BrainScope One (Device) $72.05
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Detroit
Randy Lieberman, Md, MD
Internal Medicine — Payments: $1.6M
Internal Medicine $1.6M
Dr. Philip Philip, Md Phd Frcp, MD PHD FRCP
Internal Medicine — Payments: $708,561
Internal Medicine $708,561
Shirish Gadgeel, Md, MD
Internal Medicine — Payments: $563,542
Internal Medicine $563,542
Pedro Villablanca Spinetto, M.d, M.D
Internal Medicine — Payments: $480,267
Internal Medicine $480,267
Dr. Mir Basir, D.o, D.O
Internal Medicine — Payments: $415,569
Internal Medicine $415,569
Dr. Ammar Sukari, M.d, M.D
Internal Medicine — Payments: $371,746
Internal Medicine $371,746